Thanks Mike. I've been posting some speculation on the IDEC (IDPH) thread about the possible success of their Rituxan antibody. As you may know Xoma was the first to make, and patent, chimeric anti-CD20 antibodies, of which Rituxan is but an example. And IDEC (and its Rituxan partner, Genentech) has agreed to pay Xoma royalties on sales for the right to use this technology. The first quarter reports for Xoma and IDEC will be interesting, for a change, as we can start to assess the size of Rituxan's market and the exact royalty stream Xoma will be getting from this.
And you are more than correct in making a difference between the Chicano brand of Spanish and what's spoken in other countries. I've had housemates from Argentina, Spain, Puerto Rico, among others, and some times it was hard to agree on what the "correct" way of saying things was. Of course, the Spaniards were always right (they are our British equivalents -g-).
PB |
